SynapDxRaises $6M

SynapDx Corporation, a Southborough, Mass.-based developer of blood-based diagnostic test designed to identify children with autism spectrum disorders (ASD) by age 36 months, has raised $6m in financing.

Backers include North Bridge Venture Partners and General Catalyst Partners.

The company intends to use the capital for further studies, slated to begin in 2013, and for further expansion of its executive team (, following the addition of Robert Carpenter, former lead director of Genzyme Corporation, to its board of directors.

Founded 2010 and led by Stanley Lapidus, CEO, SynapDx, who holds more than 30 patents and founded diagnostic companies Cytyc and EXACT Sciences, SynapDx develops a blood-test whose approach is to measure differences in RNA gene expression to distinguish between children with a higher risk for ASDs from those without in order to secure access to the right evaluations and treatment as early as possible.



Join the discussion